From what type of technology is Urokinase now derived?

Urokinase is now derived from recombinant technology. This method involves using genetically engineered microorganisms to produce the active form of urokinase, which was originally isolated from human urine. Recombinant technology has advanced the ability to create more consistent and pure quantities of urokinase for clinical use, allowing for better control over production and quality in comparison to traditional methods that relied on human sources.

Understanding the significance of recombinant technology is essential in the context of pharmaceuticals and biotechnology, where nearly all biologic drugs, including many antiplatelet agents, are developed using these modern techniques. In contrast, the other options listed do not accurately relate to the source of urokinase, highlighting the unique role of recombinant technology in this context.